Skip to content

Supplier News

Mylan, Teva, Actavis launch generic versions of Flomax

Mylan Pharmaceuticals Inc., Actavis Inc. and Teva Pharmaceutical Industries Ltd. this week began shipping generic versions of the branded drug Flomax, for the treatment of enlarged prostate. Mylan and Teva said Wednesday they received final approval from the Food and Drug Administration for 0.

Nicorette mini lozenge makes debut

GlaxoSmithKline Consumer Healthcare has launched a Nicorette mini-sized anti-smoking lozenge, which is designed to dissolve up to three times faster than other stop-smoking lozenges.

Takeda ships Dexilant antacid

Takeda Pharmaceuticals North America Inc. has rolled out Dexilant (dexlansoprazole) delayed-release capsules, for the treatment of heartburn and related ailments, to pharmacies in the United States. Dexilant is available in 30 mg and 60 mg capsules, Takeda said Monday.

PepsiCo enlists Rite Aid for recycling effort

Rite Aid Corp. plans to deploy Dream Machine bottle and can recycling kiosks as part of a recycling initiative by PepsiCo and Waste Management Inc. The drug store chain is one of the first national retailers to sign on to the program, starting with 150 kiosks in its North Carolina locations. Under

Eurand unveils AdvaTab Acetaminophen tablets

Eurand is offering a new licensing opportunity for retailers and health care companies with AdvaTab Acetaminophen, an orally disintegrating tablet (ODT) that incorporates its proprietary AdvaTab ODT and Microcaps taste-masking technologies.

Sandoz to acquire respiratory generics maker Oriel

Sandoz plans to acquire U.S. pharmaceuticals company Oriel Therapeutics, which the Novartis division said would give it exclusive rights to a portfolio of generic drug candidates and related technologies in the inhalable respiratory drug market. Terms of the deal weren’t disclosed.

Mylan adds new clozapine tablet dosages

Mylan Pharmaceuticals Inc. has launched 50 mg and 200 mg tablets for its geneirc antipsychotic drug clozapine. The pharmaceutical company, a subsidiary of Mylan Inc., said Monday that those clozapine dosages had U.S. sales of about $13.5 million last year, according to IMS Health data.